nach oben

International Journal of Clinical Oncology

Erschienen in:

08.12.2015 | Original Article

Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations

verfasst von: Yusuke Okuma, Yukio Hosomi, Kageaki Watanabe, Satoshi Takahashi, Tatsuru Okamura, Tsunekazu Hishima

Erschienen in: International Journal of Clinical Oncology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

The key drugs for chemotherapy of thymic carcinoma are gradually being revealed in phase II and conventional retrospective studies. Gemcitabine is regarded as one of these key drugs according to the findings of clinical trials in which it was combined with capecitabine. However, the activity of single-agent gemcitabine concerning refractory thymic carcinoma remains unclear.

Patients and methods

We conducted a retrospective review of the medical records of refractory thymic carcinoma patients previously treated with platinum-containing chemotherapy between 1980 and 2014.

Results

Of all 11 patients in this study, the objective response rate regarding gemcitabine was 36.4 % [95 % confidence interval (CI) 15.2–64.6] using the RECIST criteria and the response criteria proposed by the ITMIG. The median progression-free survival time was 4.3 months (95 % CI 0.7–11.0). The survival time from the start of gemcitabine treatment was 28.5 months (95 % CI 5.5–47.8), and from the start of first-line chemotherapy was 46.5 months (95 % CI 7.3–47.8).

Conclusions

Gemcitabine achieved a moderate response and has the potential to be used as a key drug for thymic carcinoma. Some patients treated with gemcitabine demonstrated prolonged cancer control even in later lines of chemotherapy.

Rare Cancers Europe. In: http://www.rarecancerseurope.org/. Accessed Aug 2015

Detterbeck F, Huang J (2011) ITMIG definitions and policies. J Thorac Oncol 6:S1689–S1755CrossRefPubMed

Girard N (2012) Chemotherapy and targeted agents for thymic malignancies. Expert Rev Anticancer Ther 12:685–695CrossRefPubMed

Ettinger DS, Riely GJ, Akerley W et al (2013) Thymomas and thymic carcinomas: clinical practice guidelines in oncology. J Natl Compr Canc Netw 11:562–576PubMed

Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMed

Bruning A, Mylonas I (2011) New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer. Arch Gynecol Obstet 283:1087–1096CrossRefPubMed

Jordheim LP, Seve P, Tredan O et al (2011) The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 12:693–702CrossRefPubMed

Palmieri G, Buonerba C, Ottaviano M et al (2014) Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a phase II trial. Future Oncol 10:2141–2147CrossRefPubMed

Travis W, Brambilla W, Müller-Hermelink H et al (2004) Pathology and genetics of tumors of the lung, pleura, thymus and heart. In: Chapter 3 Tumours of the thymus. Third edition. World Health Organization classification of tumors, IARC press, Lyon. Volume 10:145-248

10.

Masaoka A (2010) Staging system of thymoma. J Thorac Oncol 5:S304–S312CrossRefPubMed

11.

Huang J, Detterbeck FC, Wang Z et al (2010) Standard outcome measures for thymic malignancies. J Thorac Oncol 5:2017–2023CrossRefPubMed

12.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed

13.

Benveniste MF, Korst RJ, Rajan A et al (2014) A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria. J Thorac Oncol 9:S119–S124CrossRefPubMed

14.

Loehrer PJ Sr, Kim K, Aisner SC et al (1994) Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 12:1164–1168PubMed

15.

Agatsuma T, Koizumi T, Kanda S et al (2011) Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. J Thorac Oncol 6:2130–2134CrossRefPubMed

16.

Hirai F, Yamanaka T, Taguchi K et al (2015) A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann Oncol 26:363–368CrossRefPubMed

17.

Lemma GL, Lee JW, Aisner SC et al (2011) Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 29:2060–2065CrossRefPubMedPubMedCentral

18.

Okuma Y, Saito M, Hosomi Y et al (2015) Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy. J Cancer Res Clin Oncol 141:323–331CrossRefPubMed

19.

Giaccone G, Ardizzoni A, Kirkpatrick A et al (1996) Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14:814–820PubMed

20.

Umemura S, Segawa Y, Fujiwara K et al (2002) A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy. Jpn J Clin Oncol 32:262–265CrossRefPubMed

21.

Highley MS, Underhill CR, Parnis FX et al (1999) Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol 17:2737–2744PubMed

22.

Loehrer P, Yiannoutsos C, Dropcho S (2006) A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. Am Soc Clin Oncol 24:7079 (abstract)

23.

Hsu CH, Yeh KH, Cheng AL (1997) Thymic carcinoma with autoimmune syndrome: successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin. Anticancer Res 17:1331–1334PubMed

24.

Oberg K, Kvols L, Caplin M et al (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966–973CrossRefPubMed

25.

Girard N, Lal R, Wakelee H et al (2011) Chemotherapy definitions and policies for thymic malignancies. J Thorac Oncol 6:S1749–S1755CrossRefPubMed

26.

Kelly RJ, Petrini I, Rajan A et al (2011) Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 29:4820–4827CrossRefPubMedPubMedCentral

27.

Strobel P, Hartmann M, Jakob A et al (2004) Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 350:2625–2626CrossRefPubMed

28.

Strobel P, Bargou R, Wolff A et al (2010) Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 103:196–200CrossRefPubMedPubMedCentral

29.

Girard N, Mornex F (2011) The role of radiotherapy in the management of thymic tumors. Thorac Surg Clin 21:99–105CrossRefPubMed

30.

Zucali PA, De Pas TM, Palmieri G et al (2014) Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. ASCO Meeting Abstracts 32:7527

31.

Thomas A, Rajan A, Berman A et al (2015) Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 16:177–186CrossRefPubMedPubMedCentral

32.

Rajan A, Carter CA, Berman A et al (2014) Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol 15:191–200CrossRefPubMedPubMedCentral

33.

Le Tourneau C, Delord JP, Goncalves A et al (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16(13):1324–1334CrossRefPubMed

34.

Levêque D (2008) Off-label use of anticancer drugs. Lancet Oncol 9:1102–1107CrossRefPubMed

35.

Katsuya Y, Fujita Y, Horinouchi H et al (2015) Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer 88:154–159CrossRefPubMed

36.

Padda SK, Riess JW, Schwartz EJ et al (2015) Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol 10:500–508CrossRefPubMedPubMedCentral

37.

Okuma Y, Hosomi Y, Miyamoto S, et al (2015) Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma. J Clin Oncol 33:suppl; abstr e18565

38.

Koizumi T, Agatsuma T, Komatsu Y et al (2011) Successful S-1 monotherapy for chemorefractory thymic carcinoma. Anticancer Res 31:299–301PubMed

39.

Okuma Y, Hosomi Y, Takahashi S et al (2015) Response to cytotoxic chemotherapy in patients previously treated with palliative-intent chemotherapy for advanced thymic carcinoma. Clin Lung Cancer 16:221–227CrossRefPubMed

40.

Okuma Y, Hosomi Y, Takagi Y et al (2013) Clinical outcomes with chemotherapy for advanced thymic carcinoma. Lung Cancer 80:75–80CrossRefPubMed

41.

Liang Y, Padda SK, Riess JW et al (2015) Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. Lung Cancer 87:34–38CrossRefPubMed

42.

Watanabe N, Umemura S, Niho S et al (2015) Docetaxel for platinum-refractory advanced thymic carcinoma. Jpn J Clin Oncol 45:665–669CrossRefPubMed

43.

Wakelee HA, Padda SK, Burns M et al (2015) 2015) Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM). ASCO Meet Abstr 33:7580

44.

Giaccone G, Rajan A, Berman A et al (2011) Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol 29:2052–2059CrossRefPubMedPubMedCentral

45.

Besse B, Garassino MC, Rajan A et al (2014) A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC). ASCO Meet Abstr 32:7526

46.

Gubens MA, Burns M, Perkins SM et al (2015) A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. Lung Cancer 89:57–60CrossRefPubMed

Titel: Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations
verfasst von: Yusuke Okuma
Yukio Hosomi
Kageaki Watanabe
Satoshi Takahashi
Tatsuru Okamura
Tsunekazu Hishima
Publikationsdatum: 08.12.2015
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 3/2016
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-015-0926-0

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations

Abstract

Background

Patients and methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Patients and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Erratum to: Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer

Sarcopenia as a predictor of major hepatectomy complications: a little addition

Health insurance status and survival among patients with head and neck cancer in Japan

Human papillomavirus type-specific persistence and reappearance after successful conization in patients with cervical intraepithelial neoplasia

Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application

Incidence and severity of adverse events associated with re-irradiation for spine or pelvic bone metastases

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie